The Nifty Healthcare index has slumped by 8% to 13,790, plummeting below its moving average, due to concerns about US tariffs. Sun Pharma may experience a 5% earnings decline in FY28, while companies like Aurobindo and Cipla find temporary relief but still face potential policy-related challenges. [Source: Business Standard]

Cipla's shares reached a two-year low of ₹1,195.15 this week, dropping 20% year-to-date despite the Sensex's growth by 1.9%. This downturn is due to a significant drop in US sales, with Q3 numbers showing a 26% decrease, primarily caused by declining gRevlimid sales and disruptions in Lanreotide distribution. The EBITDA margin has been revised down to 21%.

Cipla announces that Achin Gupta will take over as CEO starting April 1, 2026, with Umang Vohra stepping down from the role. Meanwhile, Saurabh Gambhir and Satyavan Manikani are joining senior management.